Skip to main content
. 2021 Sep 14;9:729965. doi: 10.3389/fcell.2021.729965

FIGURE 1.

FIGURE 1

High hypoxia inducible factor-1α (HIF1α) staining is related with worse response of neoadjuvant therapy (NAT) containing paclitaxel and higher clinical stage in local advanced breast cancer (BC) cohort. (A) Bar plot showing NAT response and HIF1α staining results of each individual in Renji breast cancer NAT cohort. (B) Polymerase chain reaction (PCR) rate of NAT and ratio of patients reaching the AJCC stage III in different HIF1α expression groups. PCR, pathological complete response; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; NAT, neoadjuvant therapy.